dicomLAB

dicomLAB Dental Ltd.'s dental surgery planning and prosthodontic planning software technology is unique of its kind. There are other products on the market, but dicomLAB was the first to introduce a surgical and prosthetic planning software that operates entirely within a web browser application and is accessible on mobile devices and integrable into other applications. The planning software is embedded in a workflow system that guides the implantologist through the entire workflow from CT imaging to crown placement. Technical complexities, such as converting CT images into computer graphics, are performed by automation and a service center instead of the doctors, reducing the time the doctors spend on planning from a few hours to just 10-15 minutes. The co-investors of dicomLAB Dental Kft. are well-known Hungarian venture capital investors, e.g. MFB NTA, OXO Technologies, Lombard-Invest, STRT Holding. The START INNOVATION Fund has acquired a 7.28% stake with a capital investment of HUF 145.8 million. A further capital investment of HUF 90 million is under implementation.

OMIXON

Omixon Biocomputing Ltd. is an Innovation Grand Prize-winning, Hungarian-owned, Budapest-based, global molecular diagnostics company that has successfully introduced a range of products for donor organ transplantation to international markets. The company manufactures and exports one of the most advanced transplant diagnostic products available worldwide. Omixon was founded in 2011 and quickly gained the support of the research and clinical transplant community and key opinion leaders. Omixon is backed by well-known Hungarian and international venture capital investors from the technology venture capital market, such as FASTVENTURES, Lochlomond, OBC Investment, EY Biosystems. START FUTURE Private Equity Fund has invested HUF 600 million to acquire 7.5% equity stake and has provided an additional HUF 38.5 million shareholder loan. On 15 December 2023, a mandatory buyout offer from a Western European investment group was accepted by the owners. The Quota Sale & Purchase Agreement was signed on 26 April 2024, and the payment is expected to be received shortly.

Genomate Health

The goal of Genomate Health Inc. is to provide each cancer patient with effective, personalized treatment based on the unique combination of gene defects in their tumor. Genomate’s technology represents the first AI-based medical method that enables the delivery of statistically evidence-based, yet personalised treatment to cancer patients. This innovative approach revolutionizes the more effective use of current drugs and opens up opportunities for much faster development of new drugs. The technology has won several innovation awards, including The Hungarian Innovation Association and the Ministry of Innovation and Technology's IT Innovation Award; the Association of IT Enterprises' Tibor Gyurós Innovation of the Year Award; the DIGITALEUROPE and EU Commission's Unicorn Award; and American Society of Oncologists (ASCO) Congress Award for Breakthroughs in Oncology. An analysis of the SHIVA01 clinical trial data, published in the journal Nature focused on precision oncology, revealed that the personalized treatments recommended by Genomate were four times more likely to be effective (69% vs. 17%) compared to treatments suggested by oncologists. Real-life data further demonstrated that Genomate’s recommended treatments tripled the survival rate of lung cancer patients. Genomate Health’s co-investors include OKTOGON SA, CLBA Investments, and MAYO Clinic. The START FUTURE Fund has invested HUF 810 million in Genomate Health Inc.

Piszkei Malom és Pékség

Piszkei Öko Kft. is a milling and bakery company founded in 2000, located 65 kilometers from Budapest, near the Slovakian border. Its main profile is the production of traditional (non-gluten-free) breads, buns and rolls, but they also produce cheese crackers and rolls with different flavours. The company's machinery and the existing technological line are suitable for the production of other products as well. The professional co-investor intends to move more and more towards gluten-free, higher added value products in the coming years. The results of the 2016 Nielsen survey show that in Europe, 4 percent of people bought gluten-free products in 2016. By 2020, this figure had doubled due to the increasing prevalence of various lifestyle diseases, with the gluten-free market growing in popularity across Europe. Hungary follows the same trend, with 10 out of 100 people consuming gluten-free products either for health reasons or as a lifestyle choice. One of the company's significant competitive advantages is its full vertical integration in the production process (excluding crop farming), from the mill to packaging and delivery vehicles. To facilitate the company's acquisition alongside the professional co-investor, a Special Purpose Vehicle (SPV) was created, in which the START FUTURE Fund acquired a 40% ownership stake.

White Unicorn

The company is a business incubator primarily focused on early-stage healthcare, medical technology, and IT projects. It actively develops the domestic medtech ecosystem by involving universities, research centers, service companies, software and hardware developers, and other industry players. In addition to investment and operational support, companies in the portfolio gain access to a valuable national and international professional community. The incubator aims to provide seed capital and mentoring for business, IT, medical technology and other professionals to support emerging technology ventures in the healthcare sector and to create a professional community platform for academia, research and market players. White Unicorn has been awarded a HUF 250 million grant from the National Research Development and Innovation Office under the grant 2023-1.1.3-STARTUP-2023-00031. Utilizing additional private equity, the incubator plans to invest in 10-15 early-stage startups over the next two years, focusing primarily on med/healthtech and IT. In June 2024, ACCESSIO Equity Partners Zrt. acquired a 44% ownership stake in the company with an investment of HUF 30.8 million.